Not available
Quote | Sophiris Bio Inc (NASDAQ:SPHS)
Last: | $ |
---|---|
Change Percent: | 2.40% |
Open: | $0.74 |
Close: | $0.6899 |
High: | $0.74 |
Low: | $0.6765 |
Volume: | 78,918 |
Last Trade Date Time: | 02/12/2020 04:49:52 pm |
News | Sophiris Bio Inc (NASDAQ:SPHS)
Sophiris Bio plummets ( SPHS -96.3% ) after the company announces to immediately commence the process of shutting down of its operations. More news on: Sophiris Bio, Inc., Healthcare stocks news, Read more ...
SAN DIEGO and VANCOUVER, British Columbia , May 18, 2020 /PRNewswire/ -- Sophiris Bio Inc. (OTCQB: SPHS) (the "Company" or "Sophiris"), today announced that its board of directors has formally approved an immediate shutdown of the operations of the Company. The Compa...
Message Board Posts | Sophiris Bio Inc (NASDAQ:SPHS)
Subject | By | Source | When |
---|---|---|---|
SPHS: effective April 12,2022 FINRA will suspend the | Renee | investorshub | 04/11/2022 1:34:07 PM |
Still dont see a reason why this is increasing | StockLogistics | investorshub | 06/18/2021 2:32:24 PM |
13 days to file something maybe a spec | StockLogistics | investorshub | 06/17/2021 1:03:15 PM |
Why the increase today, an effort to prevent | StockLogistics | investorshub | 06/11/2021 5:00:34 PM |
Running out of real estate September 25th and | StockLogistics | investorshub | 05/25/2021 12:36:26 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO and VANCOUVER, British Columbia , May 18, 2020 /PRNewswire/ -- Sophiris Bio Inc. (OTCQB: SPHS) (the "Company" or "Sophiris"), today announced that its board of directors has formally approved an immediate shutdown of the operations of the Company. The Compa...
SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the tre...
SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseas...